PALO ALTO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced ...

Pfizer is taking a curtain call for Vyndaqel, the low-dose version of its blockbuster tafamidis franchise for the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM). Pfizer will ...

Despite formidable competition in the growing transthyretin amyloid cardiomyopathy (ATTR-CM) market, a strong early launch phase for BridgeBio Pharma’s Attruby is proving that the drug shouldn't be ...

Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Nexiguran ziclumeran (nex-z) is an investigational therapy based on CRISPR-Cas9 (clustered regularly ...

ATTR phenotypes vary by genotype as well as by gene penetrance, age, and geographic location. A new analysis examined data from untreated, symptomatic patients who had 1 of 4 variants: F64L, I68L, ...

Please provide your email address to receive an email when new articles are posted on . ALXN2220, a novel investigational depleter monoclonal antibody, was granted fast track designation by the FDA.

Transthyretin amyloidosis (ATTR) is a protein conformational disorder caused by the build-up of transthyretin, the protein carrying thyroxine and retinol in the bloodstream. While cardiomyopathy is a ...

When you have transthyretin amyloid cardiomyopathy (ATTR-CM), proteins called amyloids build up in your heart, stiffening the muscle and interfering with its ability to pump blood throughout the body.

As transthyretin amyloid cardiomyopathy (ATTR-CM) progresses, it can cause more serious problems with the heart and other parts of the body. Talking with your doctor about how the condition may ...